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Introduction
In recent years, the strategies for primary prevention of cardio-
vascular disease and the improvement of emergency therapeutic
protocols have dramatically changed the clinical outcome of
myocardial infarction, because an ever-increasing number of
patients survive the acute phase of this disease. The other aspect
of the medal consists in increased occurrence of long-term com-
plications due to adverse myocardial remodelling, mainly
impaired myocardial contractile function and heart failure [1]. In
fact, the myocardium possesses scarce regenerative potential,
being composed mainly of mature cardiomyocytes unable to
self-renew. Despite the adult heart does contain muscle stem
cells with the potential to proliferate and differentiate [2–4],
these cells are actually incapable of regenerating the damaged
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Abstract
Although the myocardium contains progenitor cells potentially capable of regenerating tissue upon lethal ischaemic injury, their actual
role in post-infarction heart healing is negligible. Therefore, transplantation of extra-cardiac stem cells is a promising therapeutic
approach for post-infarction heart dysfunction. Paracrine cardiotropic factors released by the grafted cells, such as the cardiotropic hor-
mone relaxin (RLX), may beneficially influence remodelling of recipient hearts. The current study was designed to address whether graft-
ing of mouse C2C12 myoblasts, genetically engineered to express green fluorescent protein (C2C12/GFP) or GFP and RLX (C2C12/RLX),
are capable of improving long-term heart remodelling in a rat model of surgically induced chronic myocardial infarction. One month after
myocardial infarction, rats were treated with either culture medium (controls), or C2C12/GFP cells, or C2C12/RLX cells plus exogenous
RLX, or exogenous RLX alone. The therapeutic effects were monitored for 2 further months. Cell transplantation and exogenous RLX
improved the main echocardiographic parameters of cardiac function, increased myocardial viability (assessed by positron emission
tomography), decreased cardiac sclerosis and myocardial cell apoptosis and increased microvascular density in the post-infarction scar
tissue. These effects were maximal upon treatment with C2C12/RLX plus exogenous RLX. These functional and histopathological find-
ings provide further experimental evidence that myoblast cell grafting can improve myocardial performance and survival during post-
infarction heart remodelling and dysfunction. Further, this study provides a proof-of-principle to the novel concept that genetically engi-
neered grafted cells can be effectively employed as cell-based vehicles for the local delivery of therapeutic cardiotropic substances, such
as RLX, capable of improving adverse heart remodelling.
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myocardium and improving the clinical symptoms of heart fail-
ure [5]. Therefore, the attention of many researchers has been
long-focused on extra-cardiac stem cells with the ability, at least
in principle, to differentiate into the cardiac muscle phenotype
[6]. In this context, stem cell grafting for cardiac repair is viewed
as the new frontier in the treatment of post-infarction heart 
failure [7–9]. Skeletal myoblasts, for example, have been consid-
ered promising candidates [10], mainly because they are resist-
ant to ischaemia and hence may survive within the poorly vascu-
larized myocardial scar. Further, these cells can be isolated and
expanded ex vivo from skeletal muscle biopsies of the same
patients scheduled for cell grafting therapy, with obvious
immunological and ethical advantages [6, 10]. Although
engrafted skeletal myoblasts do not exhibit the potential to dif-
ferentiate into myocardial-like cells [11], numerous studies have
demonstrated a significant improvement of the heart’s contractile
performance upon myoblast transplantation [12, 13]. A possible
explanation for this ostensible paradox has come from the results
of recent experimental studies, suggesting that the grafted cells
may release paracrine cardiotropic factors capable of inducing
collagen remodelling and neoangiogenesis in the recipient 
hearts [14, 15].
Based on the above-reported observations, it appears that
further investigations are needed to shed light on the mecha-
nisms underlying the functional advantages of myoblast grafting
in the post-ischaemic heart and to better define the possible
therapeutic protocols. A novel approach may be the combination
of myoblast cell grafting and cellular therapy, whereby cells can
act as carriers for genes encoding cardiotropic substances that
can be delivered locally [10]. Indeed, a recent study from our
group showed that the cardiotropic hormone relaxin (RLX) is
capable of improving the contractile performance of post-
infarcted swine hearts by positively influencing cardiac remodel-
ling and neo-angiogenesis [15]. RLX is a member of a peptide
hormone family, which includes three distinct RLX molecules
(denoted H1, H2 and H3, respectively), as well as insulin-like
peptides (INSL) 3 to 6 [16, 17]. In human beings, three separate
RLX genes have been found and designated RLN1, RLN2 and
RLN3 [16, 17]. Relaxin-2 (H2), encoded by the RLN2 gene, is the
major circulating form and accounts for most of the known bio-
logical effects of RLX in human beings and experimental animals.
RLX acts on both reproductive and non-reproductive tissues
[17–22] and exerts major effects on the cardiovascular system
[17, 21, 22]. Some of these effects, namely increased heart per-
fusion [23], neo-angiogenesis [24] and reduced cardiac fibrosis
by increased extracellular matrix (ECM) turnover [25], are poten-
tially relevant to cell grafting therapy. In fact, it may be specu-
lated that H2 RLX could be employed, both as a drug and as a
functional transgene, for cellular- or gene-based therapy of post-
infarction cardiac disease.
Therefore, we designed the current study to determine whether
skeletal myoblasts, wild-type or engineered to expressed RLX, and
exogenously administered RLX are capable of improving the long-
term sequelae in a rat model of chronic myocardial infarction and
to investigate the possible mechanisms involved.
Materials and methods
Generation and culture of engineered C2C12
myoblast cell lines
Mouse skeletal C2C12 myoblasts (ATCC, Manassas, VA, USA) were cul-
tured in DMEM containing 10% foetal bovine serum (Sigma, Milan, Italy).
Cells were transduced with an integrating lentiviral vector bicistronically
expressing human preprorelaxin 2 cDNA [26] and eGFP gene, or just
eGFP, under a cytomegalovirus (CMV) promoter. These cell strains have
been termed C2C12/RLX and C2C12/GFP, respectively. Day 2 super-
natants from C2C12/RLX cell cultures contained 1.8  0.2 ng/ml RLX, as
assessed by a human H2 RLX-specific ELISA [15]. Clones were selected
by cloning ring method and analysed by fluorescent microscopy and flow
cytometry for eGFP expression. Cells were grown in DMEM, containing
10% foetal bovine serum (Sigma) and 0.1% gentamycin, in a 5% CO2
atmosphere at 37C. When required for transplantation, cells were
detached using EDTA 0.1% in phosphate-buffered saline (PBS) and
mechanical scraping, centrifuged and washed twice in PBS and finally re-
suspended in complete culture medium, as described below. Cell concen-
tration was determined using a Bürker chamber and adjusted to the
amount required for individual injections.
Surgery and experimental protocols
The experimental protocol complied with the Declaration of Helsinki and
the recommendations of the European Economic Community
(86/609/CEE) on animal experimentation. Wistar male rats, weighing
250–300 g, under general anaesthesia and artificially ventilated, underwent
ligation of the left anterior descending coronary artery after the first diag-
onal branch to induce myocardial infarction, as previously described [27].
The animals were then placed in cages under controlled temperature and
high pO2 to facilitate post-operative recovery until achievement of a normal
respiratory activity and cardiac beating rate (350–450 beats/min.). Rats
were housed under standard conditions until the next experimental step.
Thirty days after surgery, the animals were divided in four experimen-
tal groups.
Group 1 – Infarcted controls (n  5). These rats were re-operated by
the same procedure as above and a 24-gauge silicone catheter was placed
in the vena cardiaca magna through the vena cava superior to deliver 1 ml
of DMEM culture medium at a 1 ml/min. perfusion rate.
Group 2 – Infarcted, RLX-treated (n  5). These rats were re-oper-
ated and catheterized as above to deliver DMEM alone. At the same time,
mini-osmotic pumps (mod. 2004; Alzet, Cupertino, CA, USA), having a
0.25 l/hr pumping rate and filled with 200 l PBS containing 33 g
human recombinant H2 RLX (kindly provided by Dr Mario Bigazzi,
Prosperius Institute, Florence, Italy), were implanted into the peritoneal
cavity. These devices permitted the delivery (i.p.) of a daily RLX dose of
1 g for 28 days.
Group 3 – Infarcted, C2C12/GFP-treated (n  5). These rats 
were re-operated and catheterized to deliver C2C12/GFP myoblasts 
(2 · 106 cells/100 g b.wt. in 1 ml DMEM).
Group 4 – Infarcted, C2C12/RLXRLX-treated (n  8). These rats
were re-operated and catheterized to deliver C2C12/RLX myoblasts (2 
106 cells/100 g b.wt. in 1 ml DMEM). Moreover, mini-osmotic pumps
(mod. 2004, Alzet) releasing 1 g/day human recombinant H2 RLX for 28
days were implanted into the peritoneal cavity, as in group 2.
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To prevent reflow, in all animals, the vena cardiaca magna was tied to
the infusion catheter for 10 min. In the previous studies used as reference
for the design of the present experimental protocol, a 5-min. occlusion of
the catheterized vena cardiaca magna allowed the settlement of about 30%
of total grafted myoblasts within the heart, evaluated as soon as 10 min.
after delivery [27, 28].
Following recovery, rats were housed under standard conditions for
further 60 days. The animals of all groups underwent daily oral administra-
tion of cyclosporine (15 mg/kg b.wt.) to obtain immune suppression and
enhance the success of C2C12 cell xenografting. Rat mortality upon the
first intervention for induction of myocardial infarction was 20–30% and
mortality upon re-operation ranged between 40% and 50%. The experi-
ment was terminated when each group comprised at least five animals.
Circulating levels of RLX in groups 2 and 4 were measured 1 month
(T2) and 2 months (T3) after osmotic pump implantation using a commer-
cial human H2 RLX ELISA kit (Immundiagnostik, Bensheim, Germany). In
the former case, animals were anaesthesized by isoflurane inhalation and
0.5 ml blood samples were collected by tail vein puncture and centrifuged
at 500 g for 15 min. at 20C to separate plasma. In the latter case, blood
samples were taken from the superior vena cava before heart removal for
tissue sampling.
Echocardiographic assessment of cardiac function
The animals of the four groups were anaesthesized and subjected to trans-
thoracic bi-dimensional M-mode echocardiography using a Sequoia 512
device (Siemens Acuson, Erlangen, Germany) equipped with a 15-MHz
probe to evaluate overall and segmental left ventricular dynamics and
hence heart contractile performance [29, 30]. The following parameters
were measured or calculated: (i ) left ventricular end-diastolic diameter,
LVEDD; (ii ) left ventricular end-systolic diameter, LVESD; (iii ) fractional
shortening, FS; (iv) left ventricular ejection fraction, LVEF; (v) myocardial
performance index, MPI, the sum of isovolumetric contraction and relax-
ation times/ejection time. This assay was carried out prior (T0) and 
1 month after (T1) the induction of myocardial infarction, as well as 1 (T2)
and 2 (T3) months after DMEM, RLX or cell delivery.
Micro-PET analysis of myocardial viability 
and performance
Positron emission tomography (PET) scans on the rats of the different
groups were performed after administration of the viability tracer 18fluoro-
deoxyglucose (18F-FDG), as previously described [31, 32]. 18F-FDG is
taken up by metabolically active cells (e.g. the uninjured cardiomyocytes),
thus allowing measurement of the volume of viable myocardium. Each ani-
mal was anaesthesized with 4% sevofluorane/oxygen, injected i.p. with
glucose solution to standardize glucose and insulin levels and, 20 min.
later, given 45 MBq 18F-FDG, injected in the tail vein in a 0.15-ml volume.
The residual dose in the syringe was measured to verify the effective dose
injected. At the end of the uptake time (30 min.), PET image acquisition
was performed with a GE eXplore Vista DR small-animal PET tomograph
(GE Medical System, Paris, France) with the anaesthesized rat placed
prone on the scanner bed (two bed positions, 15 min. each). Once the scan
was completed, the animal was allowed to wake up in a warmed recovery
cage. PET images of FDG-positive heart tissue areas were reconstructed
iteratively with a 2-D ordered-subsets expectation maximization algorithm
(OSEM 2-D) using a specific software (ECTB, Emory University, Atlanta,
GA, USA). In this manner, myocardial metabolic function and its treatment-
and time-related changes were semi-quantitatively evaluated. PET assay
was carried out 1 month after the induction of myocardial infarction (T1),
as well as 1 (T2) and 2 (T3) months after DMEM, RLX or cell delivery.
Cardiac tissue sampling and analysis
After the last functional assays at the T3 time-point, rats were killed by
lethal i.p. penthotal injection. At autopsy, cardiac tissue samples were
excised downstream the coronary occlusion, as well as from the non-
ischaemic inter-ventricular septum, for morphological analyses. Unless
otherwise stated, some tissue fragments were fixed in 3% paraformalde-
hyde in PBS, pH 7.4, dehydrated in graded ethanol and embedded in paraf-
fin; other fragments were cryoprotected in sucrose 30% in PBS, washed in
PBS and quickly frozen and stored at 80C until use.
Immunofluorescence for detection of 
eGFP-expressing cells
Cryostat sections, 10 m thick, were cut from frozen tissue samples, fixed
in paraformaldehyde vapours for 10 min. and incubated with rhodamine-
conjugated mouse monoclonal anti-eGFP (Santa Cruz, CA, USA; 1:200) to
detect engineered C2C12 cells. Negative controls were performed with
non-immune mouse serum substituted for the primary antibody. Cells
were examined and photographed under a Zeiss Axioskop fluorescence
microscope (Zeiss, Oberkochen, Germany). For optimal rendering, phase-
contrast and immunofluorescent micrographs were taken from the same
microscopic fields and then merged by a commercial image processing
software.
Ultrastructure of cardiac tissue
Cardiac tissue samples were fixed in glutaraldehyde-osmium tetroxide,
embedded in epoxy resin and routinely processed for transmission elec-
tron microscopical (TEM) observation. Other fragments, not osmium-
fixed, were used for immuno-electron microscopy to detect RLX in the
grafted C2C12/RLX cells. Ultra-thin sections were etched with 30% hydro-
gen peroxide and incubated with normal goat serum (Sigma; 1:20) to
quench nonspecific binding sites, then with rabbit polyclonal anti-H2 RLX
antibodies (Immundiagnostik; 10 g/ml) and finally with goat anti-rabbit
antibodies conjugated with 5 nm colloidal gold particles (BBInternational,
Stanstead, UK; 1:20). Sections in which non-immune goat serum was sub-
stituted for the primary antiserum were used as negative controls. The sec-
tions were counterstained with uranyl acetate and lead citrate and exam-
ined under a Jeol 1010 (Jeol, Tokyo, Japan) electron microscope at 80 kV.
Determination of fibrosis
Fibrosis in the cardiac scar was studied by qualitative and quantitative
morphological methods on paraformaldehyde-fixed, paraffin-embedded
samples. Sections 7-m were stained with a modified Azan method for
connective tissue, in which azocarminium was omitted to reduce
parenchymal tissue background. Five fields per animal were registered by
a digitizing camera applied to a light microscope with a 25 x objective, each
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field corresponding to a test area of 58,800 m2. On the digitized images,
measurements of overall surface area (SA) and optical density (OD) of the
anilin blue-stained collagen fibres were carried out using the free-share
ImageJ 1.33 image analysis program (http://rsb.info.nih.gov/ij), upon
appropriate threshold to exclude amorphous ground substance and
unstained myocardium. For each animal, a sclerosis index was calculated
by the formula: SAxODx106. Values from the five animals in each group
were then averaged.
Determination of microvessel density
Microvascular density (MVD) in the cardiac scar tissue was measured by
point counting on 2m-thick semi-thin sections of resin-embedded
samples, as described [15]. Ten microscopical fields (20  objective) per
animal were registered by the same device described above. A morphome-
tric square grid (test area, 147,000 m2; 130 test points; 12-mm distance
between line intersection points, corresponding to 30 m on the image)
was superimposed on each image. MVD was then calculated as the num-
ber of the points on transverse or slightly oblique microvessel profiles in
each test area. Measurements performed by two independent observers
were averaged.
Determination of cardiac cell apoptosis
Apoptosis detection was carried out by TUNEL assay on sections from
formalin-fixed, paraffin-embedded samples using a FragEL™–Klenow
DNA Fragmentation Detection Kit (Oncogene, San Diego, CA, USA)
according to the manufacturer’s instructions. Briefly, the sections were
rehydrated in graded ethanol and incubated with 15 mg/ml proteinase K
for 15 min. at room temperature. After rinsing in PBS, endogenous per-
oxidase was inactivated by incubating the sections in 3% H2O2 for 5 min.
at room temperature. After a further PBS rinsing, the sections were
immersed in terminal deoxynucleotidyltransferase (TdT) buffer containing
deoxynucleotidyl transferase and biotinylated dUTP, incubated in a humid
atmosphere at 37C for 90 min., and then washed with PBS. Then, the
sections were incubated at room temperature for 30 min. with peroxidase-
conjugated streptavidin and the signal was revealed with 3,3	-
diaminobenzidine. Finally, nuclear counterstaining was achieved by
Methyl green. Apoptotic nuclei were recognized by the presence of dark
brown staining, at variance with those of viable cells, which instead
appeared pale brown or green. From each sample, 4 microscopic fields
(40  objective) were chosen at random from the myocardium close to
the scar tissue. The overall number of cardiomyocyte nuclei was counted
and the percentage of the positive ones was calculated. An average of 200
nuclei was counted for per each animal. Two observers carried out the
measurements on the same microscopic fields and the individual values
were then averaged.
Determination of cycling cardiac cells
Immunocytochemical detection of the nuclear antigen Ki-67 was per-
formed on sections from formalin-fixed, paraffin-embedded samples. The
sections were dewaxed in xylene, rehydrated in graded ethanol, treated
with 2% H2O2 in methanol (v/v) for 2 min. to quench endogenous perox-
idase, then warmed for 5 min. in citrate buffer in a microwave oven to
retrieve antigens and finally incubated with mouse monoclonal anti-Ki-67
antiserum (MIB-1 clone, Dako, Milan, Italy; 1:50 in PBS) overnight at 4C.
Immune reaction was revealed by indirect immunoperoxidase method
(Vectastain Elite kit, Vector, Burlingame, CA, USA), using 3,3	-diaminoben -
zidine as the chromogen. In the negative controls, PBS was substituted
for the primary antiserum. Nuclear counterstaining was done by 
haematoxylin.
Statistical analysis
Values are means  S.E.M. of the animals in each group. Differences
between the experimental groups were evaluated by one-way ANOVA and
Newman–Keuls post-test. Calculations were made with Prism 4
(GraphPad, San Diego, CA, USA) statistical program.
Results
Echocardiography
In all the animals, surgical induction of myocardial infarction
caused a marked decay of the assayed echocardiographic param-
eters of cardiac function. Namely, 1 month after surgery (T1),
LVEF and FS were significantly reduced, whereas LVEDD, LVESD
and MPI were significantly increased in comparison with the pre-
operative (T0) values (Fig. 1). In the untreated controls (group 1),
these parameters remained substantially unchanged in the suc-
cessive measurements carried out 1 month (T2) and 2 months
(T3) after re-operation, at variance with significant improvements
in the rats subjected to the therapeutic treatments. In particular, (i )
LVEF was significantly increased in the rats which received
C2C12/GFP (group 3) and even more in those which received
C2C12/RLXRLX (group 4); (ii ) FS was significantly increased in
the rats given both RLX alone (group 2) and C2C12/RLXRLX
(group 4) at T2, and in all the treated animal groups at T3: at both
time-points, the best performance was achieved by the rats of
group 4; (iii ) LVEDD and LVESD were significantly reduced in all
the treated animal groups at T2 and even more at T3; LVEDD was
similarly improved in all the three groups, whereas LVESD was
particularly reduced in the animals receiving C2C12 engraftment;
(iv) MPI were significantly and similarly reduced in all the treated
animal groups at T2 and even more at T3.
Micro-PET analysis
Quantitative tomographic analysis of cardiac 18F-FDG uptake
showed that, 1 month after surgical induction of myocardial
infarction (T1), the rats of all the experimental groups had a
marked reduction of the overall volume of viable myocardium 
(Fig. 2). In many cases, this viability defect, appearing as a
hypo-metabolic, radio-negative region, involved the antero-septal
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left ventricular wall and was substantially similar in all the animals
examined. Treatment with C2C12/RLXRLX induced a clear-
cut, statistically significant increase (P 
 0.01) in the volume 
of viable myocardium as early as 1 month after cell grafting 
(T2) and even more at 2 months (T3), accounting for an
increase of 16% and 31%, respectively, over the values meas-
ured at T1. On the other hand, treatment with C2C112/GFP 
only significantly increased the viability of the myocardium at
T3 (P 
 0.05), whereas RLX alone had little or no effect on 
this parameter.
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Fig. 1 Echocardiographic
parameters of cardiac func-
tion at different time-points:
basal pre-operative values
(T0, grey columns), 1 month
after surgical induction of
myocardial infarction (T1,
black columns), 1 month (T2,
open columns) and 2 months
(T3, striped columns) after
the therapeutic treatments.
FS, fractional shortening;
LVEDD, left ventricular end-
diastolic diameter; LVESD,
left ventricular end-systolic
diameter; LVEF, left ventric-
ular ejection fraction; MPI,
myocardial performance
index. The number of rats
per group is reported at the
bottom of each column.
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Localization of the grafted cells in the host hearts
Relatively few immunoreactive eGFP-expressing C2C12 were
found in the scar tissue from groups 3 and 4 (Fig. 3A and B). By
visual observation, the hearts of C2C12/GFP-treated animals con-
tained lower amounts of immunoreactive cells compared with
those treated with C2C12/RLXRLX. The engrafted cells were
mainly located in the proximity of blood vessels, whereas they
were not detected in the viable myocardium not involved in post-
infarction remodelling. Immuno-electron microscopy of cardiac
scar specimens from rats transplanted with C2C12/RLX cells
revealed the occurrence of RLX-producing cells, identified by the
presence of RLX immuno-gold labelling on cytoplasmic areas
occupied by organelles involved in protein synthesis and secre-
tion, i.e. RER and Golgi cisternae (Fig. 3C). As expected, RLX-
immunoreactive cells were not found in the hearts transplanted
with C2C12/GFP (data not shown). The engrafted myoblasts could
be distinguished by the activated fibroblasts in the scar because
they never showed any signs of collagen secretion and fibre build-
up, as those described forward. Of note, none of the C2C12 cells
encountered showed any tendency to fuse into multinucleated
myotubes or to develop myofibrils, thus suggesting that they are
unable to regenerate contractile tissue at the grafting site, at least
under the current experimental conditions.
Histological features of post-infarcted hearts
By modified Azan staining (Fig. 4, upper panels), the post-infarc-
tion cardiac scar from the untreated control animals showed
densely packed bundles of collagen fibres. Conversely, samples
from rats subjected to the therapeutic treatments (groups 2 to 4)
exhibited a reduction in the amount of collagen fibres, confirmed
by morphometric analysis of tissue collagen content expressed as
sclerosis index (Fig. 4, centre panel). By TEM (Fig. 4, lower pan-
els), fibroblasts in the tissue samples from the untreated controls
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Fig. 2 Myocardial viability evaluated by micro-
PET analysis. Upper panels: representative
images of cardiac 18F-FDG uptake from post-
infarcted rats given culture medium alone (con-
trol) or C2C12/RLXRLX. A large uptake defect
of the viability tracer by the ventricular
myocardium can be seen in the control, but not in
the treated heart. Lower panel: overall viable ven-
tricular volume measured 1 month after surgical
induction of myocardial infarction (T1, black
columns), 1 month (T2, open columns) and 2
months (T3, striped columns) after the therapeu-
tic treatments. The number of rats per group is
reported at the bottom of each column.
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appeared as activated cells: their cytoplasms contained abundant
RER and large Golgi complexes and their plasma membranes were
characterized by sites of apposition to thin electron-dense fila-
ments, featuring collagen microfibrils undergoing pericellular pro-
cessing and assembly. Moreover, large collagen bundles were
present in the ECM. In rats receiving C2C12/RLXRLX, as well as
in those treated with H2 RLX alone, fibroblasts featured predomi-
nantly quiescent cells, with no evidence of pericellular collagen
microfibril assembly, and were immersed in a loose, electron-
lucent ECM with few, thin collagen fibrils. In contrast, the samples
from rats receiving C2C12/GFP showed ultrastructural features
not substantially different from those of the untreated controls.
To explore the effects of RLX on scar tissue vascularization and
angiogenesis, microvascular density (MVD) was measured.
Sections of cardiac tissue harvested from rats of groups 2, 3 and
4 exhibited a significant increase in MVD compared to the
untreated controls of group 1. No significant differences were
observed between the therapeutic treatments (Fig. 5).
Determination of apoptotic and proliferating 
cardiac cells
To provide further insight into the mechanisms of the observed
improvement of the post-infarcted hearts subsequent to thera-
peutic treatments, we examined and quantified the amount of
apoptotic and cycling cells in the myocardium surrounding the
scar. By TUNEL assay (Fig. 6), the untreated controls showed a
relatively large amount of apoptotic cardiomyocytes. Apoptotic
cells were significantly reduced in the hearts from rats sub-
jected to the therapeutic treatments, especially those of groups
2 and 4. By Ki-67 immunocytochemistry, very few positive
cycling cells were encountered: they were mostly isolated cells
of the scar tissue or sparse endothelial cells of microvessels in
the scar or the border-line myocardium (data not shown). No
differences were observed between the different experimental
groups.
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Fig. 3 Upper panels: representative micrographs of
C2C12/GFP and C2C12/RLX myoblasts grafted in the post-
infarction cardiac scar, immunostained to reveal eGFP. The
asterisks label blood vessel lumina. Merged phase contrast
and immunofluorescent images. Bars  20 m. Lower
panel: representative electron micrograph showing a
C2C12/RLX in close proximity of a microvessel, immunol -
abelled to reveal RLX by 10-nm gold particles (arrows and
inset). The particles are located on RER and Golgi profiles.
Bar  1 m.
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Plasma RLX levels
One month after the therapeutic treatments (T2), in the rats treated
with C2C12/RLXRLX and H2 RLX alone, plasma RLX levels were
82  37 and 75  29 ng/ml, respectively. Two months after the
treatments (T3), RLX plasma concentration fell below the sensitivity
of the assay. As expected, RLX levels were undetectable in all sam-
ples from untransplanted controls and C2C12/GFP-treated animals.
Discussion
Using a rat model of chronic myocardial infarction suitable for
long-term investigation of heart remodelling, we performed a
detailed functional analysis by combining echocardiographic
assessment of cardiac performance and PET-based metabolic
imaging of myocardial viability. This approach allowed us to
achieve a careful time-course evaluation of cardiac failure and of
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Fig. 4 Upper panels: representative
micrographs of anilin blue-stained sec-
tions of post-infarction cardiac scar
from the different animal groups. 
Bars  10 m. Centre panel: morpho-
metric analysis of scar tissue collagen
content, expressed as sclerosis index
(surface area · optical density/106) in
the different experimental groups. The
number of rats per group is reported at
the bottom of each column. Lower pan-
els: representative electron micro-
graphs showing fibroblasts (note the
extended RER and Golgi apparatus) and
the surrounding ECM (with varying
amounts of collagen fibres) in the dif-
ferent experimental groups. The insets
show sites of apposition of the cell’s
plasma membrane to thin electron-
dense filaments, which feature assem-
bling collagen microfibrils. The inset to
the lower right micrograph is a detail of
the Golgi area. Bar  1 m.
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the benefits afforded by the different therapeutic treatments. Taken
together, the results of the functional and histopathological analy-
ses provide further experimental evidence that stem cell grafting
can improve myocardial performance and survival during post-
infarction heart remodelling and offer background to the novel
concept that genetically manipulated grafted cells can effectively
be used for local delivery of therapeutic cardiotropic molecules
[10, 33, 34]. The current findings also indicate that RLX can be an
effective agent in protecting the post-infarcted heart from adverse
remodelling, in keeping with the emerging concept that this hor-
mone, due to its collagen-remodelling, pro-angiogenic and
vasodilatatory properties [23–25], can play a major cardioprotec-
tive role [17, 21, 22, 34].
This study confirms and extends our previous findings
obtained by transplantation of RLX-producing C2C12 cells in post-
infarcted swine, examined 1 month after cell injection [15]. The
current rat experimental model provides similar evidence that
improved ECM turnover and neo-angiogenesis are a prominent
feature of the functional benefits afforded by C2C12 cells and RLX,
even upon long-term cardiac remodelling (2 months): moreover, it
first indicates that selective homing of grafted myoblasts to the
post-infarction scar tissue in combination with local/circulating
RLX result in enhanced survival of peri-lesional myocardium.
The combination of C2C12/RLX cells, which secrete RLX at the
sites of cell engraftment, and osmotic pumps releasing exogenous
RLX appears to offer synergistic advantages. Exogenous RLX
alone, although promoting the improvement of some echocardio-
graphic (FS, LVEDD and MPI) and histopathological (sclerosis
index and microvascular density) parameters, had little or no
effects on residual myocardial viability, as assessed by micro-PET.
These findings suggest that systemic RLX administration chiefly
influences cardiac remodelling towards a less stiffened cardiac
© 2008 The Authors
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Fig. 5 Upper panels: representative micrographs of semi-
thin sections of post-infarction cardiac scar from the differ-
ent animal groups showing varying numbers of microvas-
cular profiles. Bars  10 m. Lower panel: morphometric
analysis of the relative volume density of microvessels
(MVD) over the total scar tissue in the different groups. The
number of rats per group is reported at the bottom of each
column.
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scar [17], thereby improving diastolic compliance and ventricular
contractile dynamics. When exogenous RLX was combined with
grafting of C2C12/RLX cells, we observed a further beneficial
effect, consistent with a statistically significant increase in the
overall volume of viable myocardium. This effect appears to
depend, at least in part, to the protection against myocardial cell
apoptosis. Interestingly, this fits well with the recent observation
that RLX antagonizes apoptosis in cultured rat cardiomyocytes
[35]. Considering the effects of exogenously given RLX observed
in animal models of acute myocardial infarction [36, 37], we sug-
gest that local secretion of RLX by C2C12/RLX cells could exert
paracrine effects on cardiac host tissue, favouring tissue perfu-
sion and reducing local inflammation and sclerosis. By these
mechanisms, RLX may promote survival and functional recovery
of the stunned, peri-necrotic myocardium. It is even possible that,
besides RLX, C2C12 cells could locally release other cardiotropic
substances, as suggested by the observation that transplantation
of C2C12/GFP also increases myocardial viability and cardiac
functional performance. In fact, stem cells have been reported to
release pro-survival and pro-angiogenic molecules when
engrafted in the post-ischaemic heart [38, 39]. This is consistent
with the recent ‘paracrine’ hypothesis to explain the functional
benefits of stem cell therapy in the post-infarcted, dysfunctional
heart [14, 15, 33, 34, 40].
The current findings also indicate that the retrograde coro-
nary venous route for cell delivery is safe, as the mortality upon
re-operation was similar in the treated and untreated animals,
and adequate for the injected C2C12 cells to engraft into 
the host myocardium, where they could survive for at least 
2 months after delivery. The relatively higher amounts of
C2C12/RLX cells found at termination in the post-infarction 
scar as compared with C2C12/GFP cells suggest that RLX may
© 2008 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 6 Upper panels: representative micro-
graphs of histological sections of the
myocardium surrounding the cardiac scar
taken from the different animal groups sub-
jected to TUNEL assay for apoptotic cells. The
dark-stained, positive cardiomyocyte nuclei are
indicated by arrows. Bars  10 m. Lower
panel: morphometric analysis of the percent-
age of positive nuclei over the total ones in the
different groups. The number of rats per group
is reported at the bottom of each column.
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promote cell proliferation or, most likely, may favour cell
engraftment and/or survival by re-modelling and improving the
hostile milieu of the scar tissue [34]. Interestingly, C2C12 cells
were localized mainly in the perivascular space, where they
retain their original features of poorly differentiated precursors
with no morphological sign of muscle-like differentiation. The
inability of the C2C12 myoblasts to execute a myogenic differ-
entiation programme in the cardiac scar has been previously
highlighted in a similar study in the swine in vivo [15] and can
be conceivably explained by the lack of appropriate micro-envi-
ronmental signals in a non-physiological host tissue [41]. This
finding offers additional support to the concept that trans-
planted myoblasts can improve the function of post-infarcted
heart by indirect mechanisms, independent of de novo regener-
ation of contractile tissue [7, 8, 14, 34], and that RLX may be a
candidate therapeutic to enhance efficacy of recovery.
From a practical point of view, the present study further under-
scores the therapeutic value of stem cell transplantation in post-
infarction cardiac dysfunction, especially when the grafted cells
are used as vehicle for the local release of cardiotropic substances
capable of improving adverse heart remodelling [42]. The current
findings also point to the option of using delayed rather than
immediate cell therapy following acute myocardial infarction to
achieve better efficacy, in keeping with previous reports [43].
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